Liquidia to Participate in the Jefferies London Healthcare Conference
November 11 2021 - 4:30PM
Liquidia Corporation (NASDAQ: LQDA) announced today that Mr.
Michael Kaseta, Chief Financial Officer of Liquidia, will provide
an update on the company's business during a fireside chat at the
Jefferies 2021 Virtual London Healthcare Conference being held
November 16-19, 2021 . The fireside chat will be available to
registered participants on-demand beginning at 8:00 a.m. GMT on
November 18, 2021.
A webcast of the event will be available on the investors
section of Liquidia’s website at
https://liquidia.com/investors/events-and-presentations, and will
be archived for 30 days following the event.
About Liquidia CorporationLiquidia
Corporation is a biopharmaceutical company focused on the
development and commercialization of products in pulmonary
hypertension and other applications of its PRINT® Technology. The
company operates through its two wholly owned subsidiaries,
Liquidia Technologies, Inc. and Liquidia PAH, LLC. Liquidia
Technologies has developed YUTREPIA™ (treprostinil) inhalation
powder for the treatment of pulmonary arterial hypertension (PAH).
Liquidia PAH provides the commercialization for rare disease
pharmaceutical products, such as generic Treprostinil Injection.
For more information, please visit www.liquidia.com.
Contact InformationMedia &
Investors:Jason AdairVice President, Corporate Development
and Strategy919.328.4400jason.adair@liquidia.com
Liquidia (NASDAQ:LQDA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Liquidia (NASDAQ:LQDA)
Historical Stock Chart
From Apr 2023 to Apr 2024